Cancer Research Technology
Log in Register
Menu

ZR-75-1 estrogen independent breast cancer cell line panel (1)
NEW

Info

Catalogue Number 154644
Antigen/Gene or Protein Targets Breast cancer anti-estrogen resistance genes
Parental Line ZR-75-1
Synonyms BCAR
Host Human
Tissue Breast
Disease Keywords Mammary ductal carcinoma, estrogen independent
Model Cancer Model
Relevance Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied random insertional mutagenesis using defective retroviruses to identify individual genes conferring estrogen independence.

Viral integrations were mapped within the human genome of the resulting panel of 71 tamoxifen-resistant cells lines (Cat No 154549-154619). Out of 15 candidate BCAR genes, seven were shown to directly underlie estrogen independence.

These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity.
Production Details ZR-75-1 cells were infected with amphotropic, defective murine retrovirus and plated in medium containing 1uM of 4-hydroxy-tamoxifen. Within 5 weeks after the start of selection proliferating colonies were individually picked and expanded to stable cell lines. Each cell line has a unique set of retrovirus integrations, one of which is responsible for the phenotype
Conditional No
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions RPMI 1640 medium supplemented with 10% heat-inactivated bovine calf serum (RBCS)
Notes In each cell line a single gene activated by the integration of the retrovirus underlies the resistant phenotype of that cell line.
Since this panel of cell lines represents multiple ways to escape estrogen-dependent growth, new drugs can be tested for their effectiveness to block growth of the different escape routes.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.

Dorssers et al. 1993. Mol Endocrinol. 7(7):870-8. PMID: 8413311.


Add a reference

References: 2 entries

van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.

Dorssers et al. 1993. Mol Endocrinol. 7(7):870-8. PMID: 8413311.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor